

# **B-Cell Chronic Lymphocytic Leukemia Treatment -Europe Market Status and Trend Report 2013-2023**

<https://marketpublishers.com/r/BF99301FB6DMEN.html>

Date: March 2018

Pages: 153

Price: US\$ 3,480.00 (Single User License)

ID: BF99301FB6DMEN

## **Abstracts**

### **Report Summary**

B-Cell Chronic Lymphocytic Leukemia Treatment -Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on B-Cell Chronic Lymphocytic Leukemia Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of B-Cell Chronic Lymphocytic Leukemia Treatment 2013-2017, and development forecast 2018-2023

Main market players of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe, with company and product introduction, position in the B-Cell Chronic Lymphocytic Leukemia Treatment market

Market status and development trend of B-Cell Chronic Lymphocytic Leukemia Treatment by types and applications

Cost and profit status of B-Cell Chronic Lymphocytic Leukemia Treatment, and marketing status

Market growth drivers and challenges

The report segments the Europe B-Cell Chronic Lymphocytic Leukemia Treatment market as:

Europe B-Cell Chronic Lymphocytic Leukemia Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany  
United Kingdom  
France  
Italy  
Spain  
Benelux  
Russia

Europe B-Cell Chronic Lymphocytic Leukemia Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

AMG-319  
ATTCK-20  
IDD-002  
JNJ-64052781  
Lenalidomide  
MAT-303  
MT-3724  
Others

Europe B-Cell Chronic Lymphocytic Leukemia Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinic  
Hospital  
Others

Europe B-Cell Chronic Lymphocytic Leukemia Treatment Market: Players Segment Analysis (Company and Product introduction, B-Cell Chronic Lymphocytic Leukemia Treatment Sales Volume, Revenue, Price and Gross Margin):

AB Science SA  
Amgen Inc.  
Celgene Corporation  
Dynavax Technologies Corporation  
Eisai  
Elsalys Biotech SAS  
F. Hoffmann-La Roche Ltd.  
iDD biotech SAS  
Immunomedics, Inc.

Johnson & Johnson  
Juno Therapeutics Inc.  
Molecular Templates Inc.  
Noxxon Pharma AG

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT**

- 1.1 Definition of B-Cell Chronic Lymphocytic Leukemia Treatment in This Report
- 1.2 Commercial Types of B-Cell Chronic Lymphocytic Leukemia Treatment
  - 1.2.1 AMG-319
  - 1.2.2 ATTCK-20
  - 1.2.3 IDD-002
  - 1.2.4 JNJ-64052781
  - 1.2.5 Lenalidomide
  - 1.2.6 MAT-303
  - 1.2.7 MT-3724
  - 1.2.8 Others
- 1.3 Downstream Application of B-Cell Chronic Lymphocytic Leukemia Treatment
  - 1.3.1 Clinic
  - 1.3.2 Hospital
  - 1.3.3 Others
- 1.4 Development History of B-Cell Chronic Lymphocytic Leukemia Treatment
- 1.5 Market Status and Trend of B-Cell Chronic Lymphocytic Leukemia Treatment 2013-2023
  - 1.5.1 Europe B-Cell Chronic Lymphocytic Leukemia Treatment Market Status and Trend 2013-2023
  - 1.5.2 Regional B-Cell Chronic Lymphocytic Leukemia Treatment Market Status and Trend 2013-2023

### **CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe 2013-2017
- 2.2 Consumption Market of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Regions
  - 2.2.1 Consumption Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Regions
  - 2.2.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Regions
- 2.3 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Regions

2.3.1 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Germany 2013-2017

2.3.2 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in United Kingdom 2013-2017

2.3.3 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in France 2013-2017

2.3.4 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Italy 2013-2017

2.3.5 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Spain 2013-2017

2.3.6 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Benelux 2013-2017

2.3.7 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Russia 2013-2017

2.4 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe 2018-2023

2.4.1 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe 2018-2023

2.4.2 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment by Regions 2018-2023

## **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Types

3.1.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Types

3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

3.3 Market Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Types

## **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Downstream Industry

4.2 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Major Countries

4.2.1 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Germany

4.2.2 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in United Kingdom

4.2.3 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in France

4.2.4 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Italy

4.2.5 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Spain

4.2.6 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Benelux

4.2.7 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Russia

4.3 Market Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT**

5.1 Europe Economy Situation and Trend Overview

5.2 B-Cell Chronic Lymphocytic Leukemia Treatment Downstream Industry Situation and Trend Overview

## **CHAPTER 6 B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

6.1 Sales Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Major Players

6.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in Europe by Major Players

6.3 Basic Information of B-Cell Chronic Lymphocytic Leukemia Treatment by Major

## Players

6.3.1 Headquarters Location and Established Time of B-Cell Chronic Lymphocytic Leukemia Treatment Major Players

6.3.2 Employees and Revenue Level of B-Cell Chronic Lymphocytic Leukemia Treatment Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

### 7.1 AB Science SA

7.1.1 Company profile

7.1.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.1.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of AB Science SA

### 7.2 Amgen Inc.

7.2.1 Company profile

7.2.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.2.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Amgen Inc.

### 7.3 Celgene Corporation

7.3.1 Company profile

7.3.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.3.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Celgene Corporation

### 7.4 Dynavax Technologies Corporation

7.4.1 Company profile

7.4.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.4.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Dynavax Technologies Corporation

### 7.5 Eisai

7.5.1 Company profile

7.5.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product

7.5.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Eisai

### 7.6 Elsalys Biotech SAS

- 7.6.1 Company profile
- 7.6.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
- 7.6.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Elsalys Biotech SAS
- 7.7 F. Hoffmann-La Roche Ltd.
  - 7.7.1 Company profile
  - 7.7.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.7.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
- 7.8 iDD biotech SAS
  - 7.8.1 Company profile
  - 7.8.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.8.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of iDD biotech SAS
- 7.9 Immunomedics, Inc.
  - 7.9.1 Company profile
  - 7.9.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.9.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Immunomedics, Inc.
- 7.10 Johnson & Johnson
  - 7.10.1 Company profile
  - 7.10.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.10.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.11 Juno Therapeutics Inc.
  - 7.11.1 Company profile
  - 7.11.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.11.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Juno Therapeutics Inc.
- 7.12 Molecular Templates Inc.
  - 7.12.1 Company profile
  - 7.12.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.12.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Molecular Templates Inc.
- 7.13 Noxxon Pharma AG
  - 7.13.1 Company profile
  - 7.13.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.13.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Noxxon Pharma AG



## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF B-CELL CHRONIC LYMPHOCYtic LEUKEMIA TREATMENT**

- 8.1 Industry Chain of B-Cell Chronic Lymphocytic Leukemia Treatment
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF B-CELL CHRONIC LYMPHOCYtic LEUKEMIA TREATMENT**

- 9.1 Cost Structure Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment
- 9.2 Raw Materials Cost Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment
- 9.3 Labor Cost Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment
- 9.4 Manufacturing Expenses Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF B-CELL CHRONIC LYMPHOCYtic LEUKEMIA TREATMENT**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source

- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: B-Cell Chronic Lymphocytic Leukemia Treatment -Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BF99301FB6DMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BF99301FB6DMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

